PharmaShots | Incisive News in 3 Shots

Subscribe Now

VISIBLE 2

Takeda Reports Results of Entyvio (vedolizumab SC) in P-III VISIBLE 2 Study for Moderately to Severely Active Crohn's Disease

Takeda Reports Results of Entyvio (vedolizumab SC) in P-III VISIBLE 2 Study for Moderately to Severely Active Crohn's Disease

July 22, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us